** H-shares of BeiGene 6160.HK jump 4.9% to HK$128.2, highest since Oct. 30
** Stock set for third consecutive session of gains
** Shanghai stock 688235.SS of the Chinese oncology treatments developer rises 2.5% to 180.39 yuan
** BeiGene says few of its oncology products will be included in the National Medical Insurance Drug Catalog effective Jan. 1, 2025
** Adds inclusion will benefit marketing and sales of the products
** YTD, Hong Kong stock gains 11% vs Shanghai shares' 30.4% rise
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。